Novocure (NASDAQ: NVCR) announced today that the U.S. Food and Drug Administration (FDA) has approved Optune Lua® for ...
Optune Lua received FDA approval based on data from the pivotal LUNAR trial which demonstrated significant median OS ...
Optune Lua for concurrent use with PD-1/PD-L1 inhibitors or docetaxel for adult patients with metastatic non-small cell lung ...
H.C. Wainwright analyst Emily Bodnar upgraded the rating on NovoCure (NVCR – Research Report) to a Buy today, setting a price target of ...
Optune Lua creates tumor treating fields to disrupt cancer cell division, and it is used in conjunction with PD-1/PD-L1 ...
Alongside immunotherapy or chemo, the wearable device helped patients live longer in a trial, though the results are somewhat controversial.
Novocure received a long-sought FDA approval for the use of its Tumor Treating Fields technology against metastatic non-small ...
Novocure announced on Tuesday that the FDA treated its Optune Lua wearable device for treating metastatic non-small cell lung ...
Shares of Novocure were trading higher in Tuesday's late session after the company said that the Food and Drug Administration had approved Optune Lua, its wearable treatment for certain types of lung ...